This $161,000 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop a prototype laparoscopic probe that can detect 511 keV gamma rays from PET tracers for improved identification of tumors and lymph nodes during prostate cancer surgery. The central approach involves using two back-to-back detectors with high energy...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $665,435 to The Leland Stanford Junior University to develop the first system capable of simultaneous multi-tracer Positron Emission Tomography (PET) imaging. The project aims to enable simultaneous imaging of multiple tracers by strategically choosing at least one PET tracer that emits gamma photons in cascade with their positron. This will allow differentiation of the...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $275,773 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to Dropletpharm Inc., a for-profit company. The grant supports Dropletpharm's development of microfluidic technologies to enable low-cost and distributed manufacturing of radiopharmaceuticals for clinical and research applications. Specifically, the project aims to expand...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $1,149,264 Project Grant under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program to The University of Texas MD Anderson Cancer Center. The grant supports the development of a rapid, inexpensive microfluidics-based approach for dose-on-demand production of ready-to-inject radiopharmaceuticals that can be adapted to a variety of...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) provides $505,848.59 to The Trustees of the University of Pennsylvania to develop new methods for rapidly accessing fluorine-18 labeled organic molecules for positron emission tomography (PET) imaging agents. The key objectives are to: 1) Optimize an amide C-H radiofluorination...
This Cooperative Agreement award from the Interior Business Center, under the Advanced Research Projects Agency for Health (ARPA-H) program (CFDA 93.384), provides $11,574,776 to The Leland Stanford Junior University to develop personalized radiopharmaceuticals for PET imaging-based diagnosis and targeted cancer treatment. The key products and services to be delivered include the design of custom ligands targeted to cancer cell membrane proteins, and the development of two tabletop devices....
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), will support the development of novel methods to image two different PET radiotracers concurrently in a single imaging session. The $597,766 award to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, will fund research to enable dual-tracer PET imaging, which can improve the...
The Tiny Cargo Company received a $432,000 National Science Foundation Technology, Innovation, and Partnerships Project Grant to test the scalability of an exosome isolation technology for developing an orally administered radioprotective therapeutic. The goal is to establish proof-of-concept for a safe, orally delivered drug platform capable of transporting biologic and small molecule therapeutics to treat radiation damage and related diseases. The first year of the award will determine scaling...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $295,000 to Theracea Pharma LC supports the development of innovative 18F-radiotracer kits for use in positron emission tomography (PET) imaging. The project aims to create advanced diagnostic tools to assist researchers and physicians, particularly in the field of oncology, by enabling more precise selection and assessment of cancer therapies, including immunotherapy. The...
This $1,541,316 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) will fund the development of a novel molecular imaging technology that combines positron emission tomography (PET) and ultrasound (US) imaging. The goal is to create a compact, real-time PET/US imaging system that can enable interactive scanning and real-time...